Rebecca Shatsky, MD (@Dr_RShatsky) ranks #19 among US breast cancer KOLs on X in 2026, by engagement from fellow physicians. 11 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: VIKTORIA-1, SWITCH. CMS Open Payments lists $19,181 in 2025 general payments.
At a Glance
- 3 posts naming a trial in 2026
- 2 trials discussed by name
- Breast Cancer: US #19 · 11 physicians engaged
- CMS Open Payments lists $19,181 in 2025 general payments.
This Month
What Rebecca Shatsky, MD has posted in the last 30 days. Updated November 10, 2026.
The worst part about the Switch trial proving what we knew to be true about payload resistance is that ADCs are basically all we have as far as control of brain mets and leptomeningeal disease. For our CNS disease patients chemo just doesnt cut it. #ESMO26 #Breastcancer #ADC
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
Who Amplifies Rebecca Shatsky, MD
Physicians who reposted Rebecca Shatsky, MD’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Breast Cancer | #19 | — | 11 | 14 | Full ranking |
What Colleagues Are Saying About Rebecca Shatsky, MD
2026 posts by fellow physicians that mention @Dr_RShatsky, quoted word for word.
I agree with @Dr_RShatsky and @dr_yakupergun in deciding which ADC to use in the residual disease setting port TDXD If there is no response to T-DXd and we suspect that the disease is being driven by an aggressive TNBC-like phenotype, this would be one of the few scenarios in which I would even consider adjuvant AC, which I otherwise rarely use in the Her2+ setting. On the other hand, if ER-positive luminal biology is driving the disease, which is not uncommon, I would love to see future trials incorporating SERDs and CDK4/6 inhibitors into the triple-positive adjuvant setting, particularly as we continue to learn more about the role of endocrine-based strategies in Her2+ from studies such as PATINA. Neratinib is an established option here as well, for extended Her2 blockade.
Trials Rebecca Shatsky, MD Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| VIKTORIA-1 | 2 | #10 of 23 | May 26, 2026 |
| SWITCH | 1 | #13 of 23 | Oct 26, 2026 |
Rebecca Shatsky, MD on VIKTORIA-1
Case in point for my prior statement on infographics for. AI. This infographic is straight up wrong. VIKTORIA 1 is gedatolisib + fulvestrant+ palbociclib. Not giredestrant +ribo. This stuff has to stop. @ASCO #ASCO2026 https://t.co/lAEJhnPzSb
Case in point fr my prior statement on infographics, this infographic is wrong. VIKTORIA 1 is gedatolisib + fulvestrant+ palbociclib. Not giredestrant +ribo. This stuff has to stop. @ASCO #ASCO2026 https://t.co/quuMVrlcpI
Rebecca Shatsky, MD on SWITCH
The worst part about the Switch trial proving what we knew to be true about payload resistance is that ADCs are basically all we have as far as control of brain mets and leptomeningeal disease. For our CNS disease patients chemo just doesnt cut it. #ESMO26 #Breastcancer #ADC
Rebecca Shatsky, MD’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Today was a big day in beast cancer history. The controversy started in premenopausal women by RxPonder is not more. Benefit of chemotherapy in those genomically low risk age 40+ premenopausal patients is due to ovarian suppression. Even in N2 patients, biology wins over stage. The big question is do we all go home and switch to Prosigna???#OPTIMA #ASCO2026 #bcsm #Oncology
Always interesting to see people come up to the microphone with wild very broad questions that aren’t necessarily on topic. 😳. So tough as a moderator to address these #ESMO26 I’m not disagreeing with what said… but. #Breastcancer
You know what they say, couples that present at @ASCO together stay together…. #ASCO2026 @ER_OncDoc @UCSDCancer @UCSDHealth @UCSDMedSchool #Oncology #AcademicTwitter @UCSDEMResidency #Cancer https://t.co/Ru1BOGP25u
Got to Chicago today for the NCTN/BIG vaccine and cell therapy meeting and it is HOT here. Like 89 degrees hot.😬 Likely the hottest on record for our annual meeting. Who else thinks this signifies a very unhappy planet😨🤯#ASCO2026
Made it to Madrid for #ESMO26 and man am I tired. 9 hour time difference from California. I’m always in awe of my colleagues who basically jump off the plane and start presenting and taking meetings when here I am a zombie. I am excited to hear the update to the #Natalie trial today though!!! #BreastCancer
Industry Payments
CMS Open Payments · 2025 general payments
$19,181 across 23 payments